DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/nhlscv/cancer) has announced the addition of the "Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview" report to their offering.
This report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. Cancer immunotherapy was once just a dream in the minds of physicians, clinicians and patients, but only recently (2010s era) has it actually been within reasonable reach. Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies covers three principle therapies that have been in the works for cancer patients.
One principle therapy that has been on the rise is checkpoint inhibitors. Checkpoint inhibitors are a class of monoclonal antibodies that inhibit pathways responsible for blocking the response of T-cells to antigens. Not only have results from clinical trials of these therapeutics been promising, but treatments have already been approved both in the U.S. and Europe for metastatic melanoma. There are several agents and targets covered in this section, including the September 5, 2014 approval of Merck's PD-1 inhibitor: pembrolizumab (Keytruda), as well as the future outlook of potential combination checkpoint inhibitor therapies.
Another principle therapy under investigation are anticancer vaccines. This is another major strategy surfacing in cancer therapeutics and, unlike traditional vaccines which are given to prevent illness (i.e. smallpox, measles, and pertussis), these vaccines are given to patients who already have cancer and are designed to elicit an antitumor response to even the most aggressive of cancers. Though this is a theoretically good approach to combat cancer, there have been an unfortunate number of clinical failures and the industry has gained only one U.S. approved anticancer vaccine. Combination therapies are also a possible route these vaccines will take in the future.
Finally, the last therapy addressed in this report is adoptive cellular immunotherapy. Adoptive cellular immunotherapy is when syngeneic activated T-cells are infused in patients to attack their cancers. There are a few types of cellular immunotherapies including: tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells bearing chimeric antigen receptors (CARs), and recombinant TCR technology. Improving these therapies is the goal over the next few years and researchers have been working heavily to commercialize these products and technologies.
Key Topics Covered:
- Checkpoint inhibitors
- Therapeutic anticancer vaccines
Adoptive immunotherapy for cancer
- TIL therapy
- Adoptive immunotherapy with genetically engineered T cells bearing chimeric antigen receptors (CARs)
- Recombinant TCR technology
- The future of adoptive immunotherapy for cancer
Outlook for cancer immunotherapy
CHAPTER 1: Introduction
CHAPTER 2: Checkpoint Inhibitors
CHAPTER 3: Therapeutic anticancer vaccines
CHAPTER 4: Adoptive Immunotherapy for Cancer
CHAPTER 5: Summary and Conclusions
For more information visit http://www.researchandmarkets.com/research/nhlscv/cancer